Immunic (IMUX) Competitors $0.71 +0.02 (+3.27%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.71 0.00 (0.00%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. FHTX, TRDA, LFCR, TSVT, ALLO, ADCT, AMRN, INZY, PVLA, and ANNXShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Foghorn Therapeutics (FHTX), Entrada Therapeutics (TRDA), Lifecore Biomedical (LFCR), 2seventy bio (TSVT), Allogene Therapeutics (ALLO), ADC Therapeutics (ADCT), Amarin (AMRN), Inozyme Pharma (INZY), Palvella Therapeutics (PVLA), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Foghorn Therapeutics Entrada Therapeutics Lifecore Biomedical 2seventy bio Allogene Therapeutics ADC Therapeutics Amarin Inozyme Pharma Palvella Therapeutics Annexon Foghorn Therapeutics (NASDAQ:FHTX) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Do institutionals & insiders have more ownership in FHTX or IMUX? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate FHTX or IMUX? Foghorn Therapeutics presently has a consensus target price of $12.13, suggesting a potential upside of 144.95%. Immunic has a consensus target price of $11.60, suggesting a potential upside of 1,526.93%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is FHTX or IMUX more profitable? Immunic has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -342.23%. Foghorn Therapeutics' return on equity of 0.00% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-342.23% N/A -27.28% Immunic N/A -326.95%-181.34% Which has more risk & volatility, FHTX or IMUX? Foghorn Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500. Comparatively, Immunic has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Does the media prefer FHTX or IMUX? In the previous week, Foghorn Therapeutics had 1 more articles in the media than Immunic. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for Immunic. Foghorn Therapeutics' average media sentiment score of 1.13 beat Immunic's score of 0.87 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, FHTX or IMUX? Foghorn Therapeutics has higher revenue and earnings than Immunic. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M12.21-$86.62M-$1.36-3.64ImmunicN/AN/A-$100.51M-$1.23-0.58 SummaryFoghorn Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.15M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.5821.3126.2319.90Price / SalesN/A278.47413.23113.66Price / CashN/A41.4736.1356.90Price / Book3.577.518.045.38Net Income-$100.51M-$55.05M$3.15B$248.50M7 Day Performance0.37%2.07%1.44%2.04%1 Month Performance-2.38%4.84%3.62%4.84%1 Year Performance-37.73%5.37%34.68%20.23% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.6203 of 5 stars$0.71+3.3%$11.60+1,526.9%-38.0%$66.15MN/A-0.5870FHTXFoghorn Therapeutics2.0446 of 5 stars$4.88+3.3%$12.13+148.7%-9.0%$269.22M$22.60M-3.55120News CoverageTRDAEntrada Therapeutics3.3758 of 5 stars$7.08-0.6%$25.67+262.5%-48.1%$268.72M$210.78M8.74110Trending NewsInsider TradeLFCRLifecore Biomedical1.6188 of 5 stars$7.25+4.5%$8.00+10.3%+70.3%$268.10M$128.26M-4.99690TSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440ALLOAllogene Therapeutics3.4292 of 5 stars$1.22-1.2%$8.44+595.0%-44.4%$265.76M$20K-0.99310Gap DownADCTADC Therapeutics1.6753 of 5 stars$2.67-3.8%$7.75+190.8%-19.0%$265.31M$70.84M-1.84310Gap DownAMRNAmarin0.7503 of 5 stars$12.60+0.5%$7.00-44.4%+18.1%$260.95M$228.61M-3.46360INZYInozyme Pharma3.4168 of 5 stars$4.00+0.1%$11.75+194.1%N/A$257.93MN/A-2.3650News CoveragePVLAPalvella Therapeutics3.2158 of 5 stars$23.19+5.2%$46.29+99.6%N/A$256.48M$42.81M-1.92N/AANNXAnnexon2.2575 of 5 stars$2.34-1.9%$12.50+435.3%-38.4%$256.17MN/A-1.9860News CoveragePositive News Related Companies and Tools Related Companies Foghorn Therapeutics Alternatives Entrada Therapeutics Alternatives Lifecore Biomedical Alternatives 2seventy bio Alternatives Allogene Therapeutics Alternatives ADC Therapeutics Alternatives Amarin Alternatives Inozyme Pharma Alternatives Palvella Therapeutics Alternatives Annexon Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.